New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›Fidelity›FMED

FMED

Fidelity Disruptive Medicine ETF

Active ETF Equity Theme: Healthcare Technology & Innovation Theme: Life Sciences

Not rated

The FMED Exchange Traded Fund (ETF) is provided by Fidelity. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

$33.45

+$0.22 (+0.65%) yesterday

1:30 PM 10/29/26 Closed

1D price range

$33.24$33.56

52W price range

$23.48$33.56

YTD Perf.

+22.81%

YTD Flows

Annualized volatility

Fund AuM

€48M

Share class AuM

€48M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US3160921470

TER

0.5%

Inception date

6/12/2023

Issuer

Fidelity

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
HELX Franklin Genomic Advancements ETF	+4.83%
BBP Virtus LifeSci Biotech Products ETF	+1.09%
PTH Invesco DWA Healthcare Momentum ETF	+3.69%
AAKG ARK Genomic Revolution UCITS ETF	+9.84%
WELL Harbor Health Care UCITS ETF	+2.02%
ARKG ARK Genomic Revolution ETF	+10.05%
IBBQ Invesco Nasdaq Biotechnology ETF	+1.83%
WDNA WisdomTree BioRevolution UCITS ETF	+4.83%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	+3.44%
WDNA WisdomTree BioRevolution Fund	+4.81%
IBB iShares Biotechnology ETF	+2.26%
XBI State Street SPDR S&P Biotech ETF	+3.10%
203780 Mirae Asset TIGER NASDAQ BIO ETF	+1.54%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	+1.83%
CURE Global X S&P Biotech ETF	+2.96%

API

PerformanceDec 31, 2025 - Oct 28, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

99.46%

Unavailable

0.54%

Latest FMED news

No content available for this fund

FAQ about FMED

FMED is an actively managed ETF. This ETF provides exposure to Other Equities.

FMED carries a total expense ratio (TER) of 0.5%.

FMED was introduced to the market on June 12, 2023.

Fidelity Disruptive Medicine ETF, FMED, is provided by Fidelity. Learn more about Fidelity here.

FMED oversees €48M in assets as of October 28, 2026.

FMED follows a distributing dividend policy, meaning it pays out income to investors.

As of August 31, 2026, FMED has significant geographic allocations in USA, Netherlands and United Kingdom.

As of August 31, 2026, FMED focuses largely on Healthcare.

As of August 31, 2026, FMED holds 72 positions in its portfolio, with 44.52% of assets concentrated in its top 15 holdings.

As of August 31, 2026, FMED top three holdings include 10X Genomics, Inc., Thermo Fisher Scientific, Inc. and Danaher Corp..

The base currency of FMED is USD.

Top 10 holdings

Data as of 08/31/26

10X Genomics, Inc.

5.14%

Thermo Fisher Scientific, Inc.

3.89%

Danaher Corp.

3.80%

Natera, Inc.

3.36%

argenx SE

3.18%

Lifestance Health Group, Inc.

3.00%

Revolution Medicines, Inc.

2.92%

Illumina, Inc.

2.86%

Moderna, Inc.

2.69%

Sartorius Stedim Biotech SA

2.59%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Fidelity Disruptive Medicine ETF

FAQ about FMED

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US